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Abstract 
Background: Acetylcholinesterase inhibitors (AChEIs) and memantine are commonly used in the 
management of dementia. In routine clinical practice, dementia is often monitored via the mini-mental 
state examination (MMSE). We conducted a systematic review and meta-analysis of the effects of these 
drugs on MMSE scores. Summary: Eighty trials were identified. Pooled effect estimates were in favour 
of both AChEIs and memantine at 6 months. Meta-regression indicated that dementia sub-type was a 
moderator of AChEI treatment effect with the effect of treatment versus control twice as high for 
PDD/DLB patients (2.11 MMSE points at 6 months) as for AD/VaD patients (0.91 MMSE points at 6 
months). Key messages: AChEIs demonstrate a modest effect versus control on MMSE scores which is 
moderated by dementia sub-type. For memantine the effect is smaller. 
Introduction 
Dementia is a major health concern in elderly populations worldwide which can affect many aspects of a 
person’s life and functioning. There is currently no cure for most forms of dementia but several drugs 
are used in its management. The acetylcholinesterase inhibitors (AChEIs) were developed as a 
consequence of the cholinergic hypothesis of cognitive decline [1] and the NMDA receptor agonist 
memantine as a consequence of an hypothesised role of the glutamatergic system in neurodegeneration 
[2]. The effectiveness of these treatments has been evaluated in a large number of randomised 
controlled trials (RCTs) across functional, global, cognitive and neuropsychiatric domains [3-5]. This 
review focuses on their effects on cognition.  
Measures  of global cognition include the mini-mental state examination (MMSE) [6], the Alzheimer’s 
disease assessment scale - cognitive subscale (ADAS-cog) [7], and the Severe Impairment Battery (SIB) 
[8], which focuses on those with severe cognitive impairment. Existing meta-analyses tend either to 
consider cognitive outcomes on the ADAS-cog or SIB [9] or to use standardised mean differences to 
combine results from several scales [10]. In this review results are analysed relating to the MMSE scale 
specifically. A small number of existing meta-analyses combine cognitive outcomes on the MMSE; 
however, these are mainly focused on diagnostic and medication subgroups and do not cover all 
available trials. The largest of these includes only 21 MMSE effect estimates [11], less than half of the 
number included in this review. 
The MMSE is the scale most often used to monitor dementia severity and progression in routine clinical 
practice, and thus the advantage of reviewed outcomes on this scale is better clinical interpretability 
and relevance to routine care.  In addition, the volume of evidence can be substantially increased by the 
inclusion of ADAS-cog results translated to MMSE scale equivalents. 
Methods 
A protocol for this systematic review was prospectively registered on PROSPERO and can be found at 
https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015025892.  
Search strategy 
A two-tier search strategy was employed to identify relevant trials for inclusion in this review. First, 
existing systematic reviews and meta-analyses assessing the drugs of interest were identified and 
citations to included trials extracted. Following this, additional searches subdivided by dementia 
diagnosis and, where necessary, drug received, were conducted to identify trials published since the 
date of the most recent review. 
Searches were conducted using the Web of Science, MEDLINE, PsycINFO, EMBASE and CINAHL 
databases. Final searches were conducted in March 2017. Searches were combinations of: (i) drug 
names e.g. “donepezil”, “galantamine”, “rivastigmine”, “memantine”; (ii) diagnoses e.g. “Alzheimer*”, 
“vascular dement*”, “lewy* bod*”, “Parkinson* disease dement*”; and (iii) “randomi?ed” and “trial”. A 
full list of search terms used is provided in the supplementary material. Further searches were carried 
out using the International Clinical Trials Registry Platform (ICTRP) and industry trial registers to identify 
unpublished trials. References and citing articles of selected trials were assessed to identify further trials 
for inclusion.  
Study selection criteria and data extracted 
Trials were included if they met the following criteria: (i) a randomised trial designed to evaluate the 
effectiveness of AChEI monotherapy, memantine monotherapy or memantine treatment in a group of 
patients some, but not all, of whom received a concurrent AChEI; (ii) treatments compared to a control 
group receiving placebo or no treatment; (iii) participants in the trial diagnosed with Alzheimer’s disease 
(AD), vascular dementia (VaD), Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB) or 
frontotemporal dementia (FTD); (iv) at least one of the MMSE or ADAS-cog used as an outcome; and (v) 
sufficient data provided, defined as at least one treatment effect estimate and associated standard error 
(SE) on either the MMSE or ADAS-cog. Treatment effect estimates used included change score 
differences and time point differences. In some cases, effect estimates and SEs had to be calculated 
from other statistics (for example, confidence intervals). 
 
From each trial, data were extracted on: (i) Trial design – duration, inclusion and exclusion criteria, 
numbers of patients randomised to each arm, intervention and control conditions, type of 
randomisation, details on blinding, cognitive assessments and measurement times; (ii) Analysis 
approaches – analysis method, missing data methods and effect size estimate used; and (iii) Trial data – 
baseline data, attrition and adherence rates, treatment effect estimates and SEs.  
 
Study selection and data extraction were conducted by one reviewer (RK) and a sample of each was 
checked by a second reviewer (NM). Reviewers agreed on study selection in 99% of cases and 
agreement regarding data extraction was also high: 87.5% for risk of bias assessment, 82.8% for baseline 
measures and 75% for effect estimates. Most effect estimate discrepancies were due to 
miscommunication on how these were extracted. All discrepancies were discussed and resolved. 
 
ADAS-cog translation 
 
The objective of the meta-analysis was to estimate the treatment effect on the MMSE; however, effect 
estimates on the ADAS-cog were also collected and translated, since both scales measure global 
cognition. Baseline measures from the 36 trials which measured both were used to translate. MMSE 
scores range from 0 to 30 and ADAS-cog scores from 0 to 70 and both MMSE=30 and ADAS-cog=0 
represent healthy cognition. Thus, a linear regression of ADAS-cog on MMSE with intercept fixed at 30 
was fitted. The resulting model was: MMSE=30-0.42*ADAS-cog, with a squared multiple correlation of 
0.679 suggesting fairly good fit. Translation of both treatment effect estimates and SEs required only the 
coefficient. Treatment effect estimates were translated using MMSE=-0.42*ADAS-cog, and the SEs using 
MMSE=0.42*ADAS-cog. 
 
Risk of bias assessment 
The risk of bias in included studies was assessed using the Cochrane risk of bias tool [12]. This 
determines whether the risk of internal bias under a series of domains is low, high or unclear. These 
were combined so that a trial rated low in all domains was at low risk of bias. One domain, reporting 
bias, was excluded from the combination, since trial protocols were required to assess it but were not 
available for most included trials due to their age. 
Statistical analyses 
Random-effects meta-analysis [13] was used to combine trial results. This was conducted separately for 
AChEIs and memantine. Pooled effects were estimated at 3, 6 and 12 months (+14 days) after treatment 
initiation. Effect estimates were also considered in AChEI drug subgroups. Heterogeneity was assessed 
using the I2 statistic [14] and publication bias using funnel plots and Begg and Mazumdar’s rank 
correlation test [15]. All statistical analyses were conducted using R [16] and the metafor package [17]. 
Meta-regressions were conducted to assess the impact of data quality on effect size estimates and test 
potential moderators. The data quality factors were: (i) the inclusion of translated results; and (ii) the 
risk of bias assessment overall rating. The hypothesised potential moderators were: (i) AChEI (donepezil, 
galantamine or rivastigmine); (ii) dementia diagnosis (AD, VaD, PDD/DLB or FTD); (iii) baseline MMSE 
score; and (iv) date of publication (before or after 2000). All were categorical factors except baseline 
MMSE, which was continuous. The Knapp and Hartung adjustment [18] was used to account for 
uncertainty in the assessment of residual heterogeneity. The omnibus test of coefficients was used to 
identify factors significant at the 5% and 1% levels. 
Results 
Literature search results 
The search for systematic reviews identified 522 citations of which 52 were relevant, and these included 
194 citations to trials. An additional 857 citations were identified by further searches for trials, resulting 
in 1051 possible citations. After removal of duplicates, title and abstract screening, and full text 
screening, 84 references about 74 trials met the inclusion criteria. Searches in ICTRP and industry 
registers and citation tracking identified a further 6 trials for inclusion. In total, 80 trials met the 
inclusion criteria. The process of identifying these is detailed in Figure 1.  
Characteristics of included studies 
Of the included trials summarised in Table 1, half (40) investigated donepezil and the others were evenly 
split amongst galantamine (13), rivastigmine (14) and memantine (13). The majority of the trials (55) 
were conducted in patients with AD. Other diagnoses were VaD (9), AD and VaD (4), PDD or DLB (10) 
and FTD (2). Dementia severity ranged from mild in some trials to severe in others. The trials lasted 
between 4 and 104 weeks and many recorded outcome measures at intermediate time points. Forty-
eight trials provided MMSE outcomes, twenty-four ADAS-cog and the remainder reported a mixture of 
the two.  
The average baseline age in AChEI trials was 73.8 years and in memantine trials was 75.9 years. The 
proportion of women was slightly more than half in the AChEI trials (mean 57.5%; range 7.1%-84.6%), 
and the memantine trials (mean 56.3%; range 25%-73.8%). The mean baseline MMSE was higher in the 
AChEI trials (18.6 points) than in the memantine trials (16.5). 
Risk of bias assessment 
The Cochrane risk of bias tool was applied to each trial and the final column of Table 1 records overall 
ratings. Risk of bias was low in 14 trials, high in 45 trials and unclear in 21 trials. The large number of 
trials rated high risk was mainly due to missing data methods combined with relatively high volumes of 
missing data. The majority of trials used observed case or last observation carried forward analyses 
which both introduce a significant risk of bias in the presence of missing data. 
Meta-analysis results 
AChEIs – 3 months 
At 3 months (+14 days) after treatment initiation, 42 trials provided 60 estimates of treatment effect. 
The pooled effect estimate (Figure 2) was 1.08 MMSE points (95% CI 0.92-1.23). There was evidence of 
heterogeneity (I2=68.2%) and this was later explored via meta-regression. Begg and Mazumdar’s rank 
test suggested some publication bias (p=0.01) and the funnel plot supported this (Figure 3); however, 
the patterns did not seem overly concerning. In the drug subgroups the treatment effects ranged from 
0.98 (95% CI 0.32-1.63) for rivastigmine to 1.15 (95% CI 0.69-1.61) for donepezil 3-5mg/d. 
AChEIs – 6 months 
At 6 months (+14 days) after treatment initiation, 38 trials provided 52 estimates of treatment effect. 
The pooled effect estimate was 1.00 (95% CI 0.83-1.16; Figure 4), and there was evidence of 
heterogeneity (I2=69.9%). Neither the funnel plot nor the rank correlation test (p=0.385) suggested 
publication bias. The effect estimates in treatment subgroups ranged from 0.69 (95% CI 0.43-0.95) for 
rivastigmine to 1.39 (95% CI 0.79-2.00) for galantamine. 
AChEIs – 12 months 
At 12 months (+14 days) after treatment initiation, 4 trials provided estimates of treatment effect. The 
pooled effect estimate was 1.10 (95% CI 0.48-1.72; Figure 5). There was evidence for heterogeneity 
(I2=79%); however, the funnel plot did not suggest any obvious publication bias and there were too few 
estimates for a formal test. 
Memantine – 3, 6 and 12 months 
Treatment effect estimates were provided by 12 memantine trials: 4 at 3 months; 8 at 6 months; and 3 
at 12 months after treatment initiation. The pooled effect estimates at each time point were in favour of 
treatment though were much smaller than those for the AChEIs (Figure 6). At 12 months the pooled 
effect did not reach significance (0.41, 95% CI -0.44 to 1.26). At all 3 time points the I2 values were small 
suggesting little heterogeneity. 
Meta-regressions 
High I2 values observed for the AChEI meta-analyses at 3 and 6 months suggested considerable 
variability in the effect estimates; this was investigated further via meta-regression. Factors investigated 
were data quality measures and potential moderators, as listed in the methods section. Tables 2 and 3 
provide meta-regression coefficients, associated p-values and the p-value for the omnibus test of 
parameters at 3 and 6 months respectively. For categorical factors, coefficients are the difference in 
average effect estimates for each category versus the reference category; for continuous factors, they 
are the relation between the factor and the effect estimate. Factors for which the omnibus test of 
parameters was significant at the 5% and 1% levels are highlighted.  
A true moderator of treatment effect would be expected to last over time, thus, only factors significant 
at both 3 and 6 months were considered. Dementia sub-type diagnosis was the only factor significant at 
both 3 months (p=0.009) and 6 months (p=0.007). Examination of diagnostic subgroup results suggested 
that the effects in the AD and VaD subgroups were the same but those in the PDD/DLB subgroup were 
different. 
Meta-analyses in diagnosis subgroups 
At 3 months the pooled effect estimate in the AD/VaD subgroup was 0.97 MMSE points (95% CI 0.85-
1.10) and in the PDD/DLB subgroup 1.99 (1.18-2.81). At 6 months the effect in the AD/VaD subgroup 
was 0.91 (0.77-1.05) and in the PDD/DLB subgroup was 2.11 (0.61-3.61). All four trials providing an 
effect estimate at 12 months were in the AD/VaD subgroup. The memantine trials provided too few 
trials for meta-regression to be conducted; however, at both 6 months and 12 months the effects in the 
PDD/DLB subgroup were significantly higher (1.90 points at 6 months and 1.80 points at 12 months) 
than those in the AD/VaD subgroup (0.36 points at 6 months and 0.31 points at 12 months). 
Discussion  
This review identified 80 trials evaluating the effects of donepezil, galantamine, rivastigmine and 
memantine on cognitive function in dementia, more than in any previous review. Cognitive effects were 
extracted on the MMSE, the outcome of interest, or the ADAS-cog. Baseline measures from 36 trials 
which measured both were used to enable translation of ADAS-cog results to the MMSE scale. This 
allowed the inclusion of 24 additional trials and results at additional time points from a further 8 trials. 
The large number of studies included in this review is one of its strengths and this number is increased 
through the translation of ADAS-cog results. The translation relationship has good R2; however, this 
relationship has not been used elsewhere and should therefore be treated as preliminary and requiring 
confirmation. 
Meta-regressions of the AChEI results at 3 and 6 months identified one moderator of treatment effect, 
dementia sub-type diagnosis. Treatment effects were smaller for those patients diagnosed with AD or 
VaD (0.97 MMSE points at 3 months and 0.91 points at 6 months) than those diagnosed with PDD or DLB 
(1.99 points at 3 months and 2.11 points at 6 months).  All trials reporting effects at 12 months were for 
AD or VaD patients and these indicated a similar effect to those at 3 and 6 months (1.10 points). The 
higher response seen in the PDD/DLB group is consistent with previous results [19] and may be due to 
the greater cholinergic deficit seen in these conditions [20]. The effects observed in the AD/VaD 
subgroup are somewhat smaller than those in a previous review of AChEIs in AD only [5]. This may be 
due to the inclusion of VaD results, which evidence suggests may give rise to more mixed findings on 
AChEI effect [21,22]; however, meta-regression indicated no significant differences between AD and 
VaD subgroups. Whilst these drugs are only licensed for the use in AD or PDD, there is evidence that 
they are widely used for patients with DLB and VaD in routine clinical practice [23], and thus the 
inclusion of these trial results was felt to be appropriate. 
The number of trials providing estimates of memantine treatment effects was much smaller and it was 
not possible to conduct meta-regression analyses; however, results were calculated for the previously 
identified subgroups. In the AD/VaD subgroup the effects were small and in favour of treatment (0.65 
MMSE points at 3 months, 0.36 points at 6 months and 0.31 points at 12 months). Again, the effects in 
the PDD/DLB subgroup were higher (1.90 points at 6 months and 1.80 points at 12 months). Few of 
these effects were significantly different from zero.  
Through the results of this review, we sought to increase clinical interpretability and relevance to 
routine care since they are estimated on the MMSE, the scale most often used to monitor dementia in 
clinical practice. Estimation of MMSE effects also potentially enables results to be compared, contrasted 
and in future combined with observational findings from routine clinical practice. The AChEI results 
suggest a treatment effect of around one MMSE point at 3, 6 and 12 months after treatment initiation. 
Since studies have suggested that the annual rate of MMSE decline amongst dementia patients is 4 to 5 
MMSE points [24], such an effect estimate is modest: equivalent to an approximately 3 month delay in 
cognitive decline. However, while the effect sizes are small, they could have a significant impact in terms 
of costs and hospital or nursing home admissions, which have both been shown to be linked to level of 
cognitive function as measured by the MMSE score [25]. In addition, the length of time for which these 
benefits continue may be of interest [23]. 
Use of the MMSE scale makes the results of this review more clinically applicable; however, there are 
several limitations to this scale. It suffers from both floor and ceiling effects [26], though these should 
not be of particular concern for the trials included in this study. In addition, it is particularly suitable for 
measuring the cognitive deficits observed in AD and may be less sensitive to those in VaD [27] or FTD 
[28]. However, the latter has little impact in the current review since only one included trial concerned 
FTD and, as mentioned, no significant differences were found between AD and VaD sub-groups in meta-
regressions. 
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Table 1: Characteristics of included studies (CVD=cerebrovascular disease, CADASIL=Cerebral 
Autosomal-Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy, PRC=prolonged-
release capsule, BID=twice daily, TID=three-times daily) 
Study Diagnosis Duration 
(weeks) 
Cognitive 
measure 
Trial arms (n) Risk of bias 
Donepezil 
Frolich et al., 
2011[29] 
AD 12 MMSE 5 or 10mg/d (161) 
Placebo (164) 
Unclear 
Gault et al., 
2015[30] 
AD 12 ADAS-cog 10mg/d (68) 
Placebo (68) 
Low 
Gelmacher et al., 
2000[31] 
AD 12 MMSE Donepezil (6) 
Placebo (6) 
Unclear 
Marek et al., 
2014[32] 
AD 12 MMSE 10mg/d (66) 
Placebo (66) 
High 
Peng et al., 2005[33] AD 12 MMSE 5mg/d (46) 
Placebo (43) 
High 
Rogers et al., 
1998a[34] 
AD 12 MMSE 5mg/d (157) 
10mg/d (158) 
Placebo (153) 
High 
NCT00777608  AD 12 ADAS-cog 5 or 10mg/d (53) 
Placebo (53) 
High 
Howard et al., 
2007[35] 
AD 12 MMSE 10mg/d (128) 
Placebo (131) 
Low 
Moraes et al., 
2008[36] 
AD 13 ADAS-cog 5mg/d (11) 
Placebo (12) 
Unclear 
Sole-Padulles et al., 
2013[37] 
AD 13 MMSE 10mg/d (8) 
Placebo (7) 
High 
Haig et al., 2014[38] AD 14 MMSE 10mg/d (60) 
Placebo (63) 
Low 
Black et al., 2007[39] AD 24 MMSE 10mg/d (176) 
Placebo (167) 
High 
Burns et al., 
1999[40] 
AD 24 ADAS-cog 5mg/d (271) 
10mg/d (273) 
Placebo (274) 
Unclear 
Feldman et al., 
2000[41] 
AD 24 MMSE 10mg/d (144) 
Placebo (146) 
Unclear 
Gold et al., 2010[42] AD 24 ADAS-cog 10mg/d (84) 
Placebo (166) 
High 
Homma et al., 
2000[43] 
AD 24 ADAS-cog 5mg/d (134) 
Placebo (129) 
Unclear 
Jia et al., 2017[44] AD 24 MMSE 5mg/d (156) 
Placebo (156) 
Low 
Maher-Edwards et 
al., 2011[45] 
AD 24 ADAS-cog 10mg/d (67) 
Placebo (63) 
High 
Mazza et al., 
2006[46] 
AD 24 MMSE 5mg/d (25) 
Placebo (26) 
High 
Gault et al., 
2016[47] 
AD 24 MMSE 10mg/d (76) 
Placebo (104) 
Unclear 
Rogers et al., 
1998b[48] 
AD 24 MMSE 
ADAS-cog 
5mg/d (154) 
10mg/d (157) 
Placebo (162) 
High 
Seltzer et al., 
2004[49] 
AD 24 MMSE 
ADAS-cog 
10mg/d (96) 
Placebo (57) 
High 
Tune et al., 2003[50] AD 24 ADAS-cog 10mg/d (14) 
Placebo (14) 
 
Unclear 
Maher-Edwards et 
al., 2015[51] 
AD 24 MMSE 
ADAS-cog 
5 or 10mg/d (152) 
Placebo (145) 
High 
dos Santos Moraes 
et al., 2006[52] 
AD 26 ADAS-cog 10mg/d (17) 
Placebo (18) 
Low 
Winblad et al., 
2006[53] 
AD 26 MMSE 10mg/d (128) 
Placebo (121) 
High 
Winblad et al., 
2001[54] 
AD 52 MMSE 10mg/d (142) 
Placebo (144) 
Unclear 
Mohs et al., 
2001[55] 
AD 54 MMSE 10mg/d (214) 
Placebo (217) 
High 
Bentham et al., 
2004[56] 
AD or 
AD+VaD 
12 MMSE 5mg/d (282) 
Placebo (283) 
High 
Tariot et al., 
2001[57] 
AD or 
AD+CVD 
24 MMSE 10mg/d (103) 
Placebo (105) 
High 
Black et al., 2003[58] VaD 24 MMSE 
ADAS-cog 
5mg/d (198) 
10mg/d (206) 
Placebo (199) 
High 
Roman et al., 
2010[59] 
VaD 24 MMSE 5mg/d (648) 
Placebo (326) 
High 
Wilkinson et al., 
2003[60] 
VaD 24 MMSE 5mg/d (208) 
10mg/d (215) 
Placebo (193) 
High 
Dichgans et al., 
2008[61] 
CADASIL 18 MMSE 10mg/d (86) 
Placebo (82) 
Unclear 
Aarsland et al., 
2002[62]  
PDD 10 MMSE 5 or 10mg/d (8) 
Placebo (6) 
High 
Ravina et al., 
2005[63] 
PDD 10 ADAS-cog 5mg/d (11) 
Placebo (11) 
High 
Leroi et al., 2004[64] PDD 18 MMSE 10mg/d (7) 
Placebo (9) 
Unclear 
Dubois et al., 
2012[65] 
PDD 24 MMSE 
ADAS-cog 
5mg/d (195) 
10mg/d (182) 
Placebo (173) 
High 
Ikeda et al., 
2015[66] 
DLB 12 MMSE 5mg/d (46) 
10mg/d (47) 
Placebo (49) 
High 
 
Mori et al., 2012[67] DLB 12 MMSE 3mg/d (35) 
5mg/d (33) 
Low 
10mg/d (37) 
Placebo (35) 
Galantamine 
Wilkinson and 
Murray, 2001[68] 
AD 12 ADAS-cog 18mg/d (88) 
24mg/d (56) 
36mg/d (54) 
Placebo (87) 
High 
Kadir et al., 2008[69] AD 13 MMSE 8-16mg/d (12) 
Placebo (6) 
Unclear 
Rockwood et al., 
2001[70] 
AD 13 ADAS-cog 24-32mg/d (261) 
Placebo (125) 
High 
Rockwood et al., 
2006[71] 
AD 16 ADAS-cog 16-24mg/d (64) 
Placebo (66) 
Unclear 
Tariot et al., 
2000[72] 
AD 22 ADAS-cog 8mg/d (140) 
16mg/d (279) 
24mg/d (273) 
Placebo (286) 
Unclear 
Brodaty et al., 
2005[73] 
AD 26 ADAS-cog 16-24mg/d (237) 
16-24mg/d PRC (320) 
Placebo (324) 
High 
Raskind et al., 
2000[74] 
AD 26 ADAS-cog 24mg/d (212) 
32mg/d (211) 
Placebo (213) 
High 
Wilcock et al., 
2000[75] 
AD 26 ADAS-cog 24mg/d (220) 
32mg/d (218) 
Placebo (215) 
High 
Likitjaroen et al., 
2011[76] 
AD 26 MMSE 16mg/d (14) 
Placebo (11) 
Unclear 
Hager et al., 
2014[77] 
AD or 
AD+CVD 
104 MMSE 18-24mg/d (1028) 
Placebo (1023) 
Low 
Erkinjuntti et al.,  
2002[78] 
VaD or 
AD+CVD 
26 ADAS-cog 24mg/d (396) 
Placebo (196) 
High 
Auchus et al., 
2007[79] 
VaD 26 ADAS-cog 24mg/d (397) 
Placebo (391) 
High 
Litvinenko et al., 
2008[80]  
PDD 24 MMSE 16mg/d (21) 
Placebo (20) 
High 
Rivastigmine      
Koch et al., 2014[81] AD 4 MMSE 4.6mg/d (10) 
Placebo (10) 
Unclear 
Mowla et al., 
2007[82] 
AD 12 MMSE 6-12mg/d (41) 
Placebo (40) 
Unclear 
Iranmanesh et al., 
2012[83] 
AD 12 MMSE 3mg/d (16) 
Placebo (16) 
Unclear 
Agid et al., 1998[84] AD 13 MMSE 4mg/d (136) 
6mg/d (133) 
Placebo (133) 
High 
Forette et al., 
1999[85] 
AD 18 ADAS-cog 12mg/d BID (45) 
12mg/d TID (45) 
High 
Placebo (24) 
Winblad et al., 
2007[86] 
AD 24 MMSE 12mg/d capsule (297) 
9.5mg/d patch (293) 
17.4mg/d patch (303) 
Placebo (302) 
High 
NCT00423085 AD 24 MMSE 9mg/d patch (284) 
18mg/d patch (287) 
Placebo (288) 
High 
Rosler et al., 
1999[87] 
AD 26 MMSE 1-4mg/d (243) 
6-12 mg/d (243) 
Placebo (239) 
High 
Corey-Bloom et al., 
1998[88] 
AD 26 MMSE 
ADAS-cog 
1-4mg/d (233) 
6-12 mg/d (231) 
Placebo (235) 
High 
Feldman and Lane, 
2007[89] 
AD 26 MMSE 
ADAS-cog 
2-12mg/d BID (229) 
2-12mg/d TID (227) 
Placebo (222) 
Unclear 
Karaman et al., 
2005[90] 
AD 52 MMSE 12mg/d (24) 
Placebo (20) 
High 
Ballard et al., 
2008[91]  
VaD 24 MMSE 3-12mg/d (365) 
Placebo (345) 
High 
Mok et al., 2007[92] VaD 26 MMSE 6mg/d (20) 
Placebo (20) 
Unclear 
Emre et al., 2004[93] PDD 24 MMSE 3-12mg/d (362) 
Placebo (179) 
High 
Memantine      
Fox et al., 2012[94] AD 12 MMSE 20mg/d (74) 
Placebo (79) 
Low 
Bakchine and Loft, 
2007[95] 
AD 24 ADAS-cog 20mg/d (318) 
Placebo (152) 
Low 
Peskind et al., 
2006[96] 
AD 24 ADAS-cog 20mg/d (201) 
Placebo (202) 
Low 
Wang et al., 
2013[97] 
AD 24 MMSE 20mg/d (13) 
Placebo (13) 
Unclear 
Reisberg et al., 
2003[98] 
AD 28 MMSE 20mg/d (126) 
Placebo (126) 
High 
Ashford et al., 
2011[99] 
AD 52 ADAS-cog 20mg/d (7) 
Placebo (6) 
High 
Wilkinson et al., 
2012[100] 
AD 52 MMSE 20mg/d (134) 
Placebo (144) 
Low 
Orgogozo et al., 
2002[101] 
VaD 28 MMSE 20mg/d (165) 
Placebo (156) 
High 
Wilcock et al., 
2002[102] 
VaD 28 MMSE 
ADAS-cog 
20mg/d (295) 
Placebo (284) 
Low 
Leroi et al., 
2009[103] 
PDD 16 MMSE 20mg/d (11) 
Placebo (14) 
High 
Aarsland et al., 
2009[104] 
PDD/DLB 24 MMSE 20mg/d (35) 
Placebo (40) 
Low 
Boxer et al., 
2013[105] 
FTD 26 MMSE 20mg/d (39) 
Placebo (42) 
Low 
Vercelletto et al.,  
2011[106] 
FTD 52 MMSE 20mg/d (26) 
Placebo (26) 
High 
 
 
Table 2: Meta-regressions of effects at 3 months. Coefficients, associated p-values and omnibus test of 
parameters p-value provided. *=significant at 5% level. **=significant at 1% level. ref=reference 
category. 
Factor Levels Number 
of trials 
Coefficient (p-value) Omnibus test p-value 
Translation to MMSE MMSE 
ADAS-cog 
28 
32 
ref 
-0.471 (0.007) 
 
0.007** 
Risk of bias rating Low 
Unclear 
High 
8 
13 
39 
ref 
-0.371 (0.307) 
-0.346 (0.269) 
 
0.521 
Medication Donepezil 
Galantamine 
Rivastigmine 
37 
17 
6 
ref 
0.010 (0.961) 
-0.153 (0.612) 
 
0.864 
Diagnosis AD 
VaD 
PDD/DLB 
46 
6 
8 
ref 
-0.211 (0.373) 
0.806 (0.005) 
 
0.009** 
Baseline MMSE NA 55 -0.069 (0.092) 0.092 
Date Pre 2000 
2000 onwards 
26 
34 
ref 
0.068 (0.703) 
 
0.703 
 
 
Table 3: Meta-regressions of effects at 6 months. Coefficients, associated p-values and omnibus test of 
parameters p-value provided. *=significant at 5% level. **=significant at 1% level. ref=reference 
category. 
Factor Levels Number 
of trials 
Coefficient (p-value) Omnibus test p-value 
Translation to MMSE MMSE 
ADAS-cog 
35 
17 
ref 
0.117 (0.540) 
 
0.540 
Risk of bias rating Low 
Unclear 
High 
3 
9 
40 
ref 
0.269 (0.579) 
0.329 (0.443) 
 
0.735 
Medication Donepezil 
Galantamine 
Rivastigmine 
27 
11 
14 
ref 
0.320 (0.139) 
-0.370 (0.133) 
 
0.033* 
Diagnosis AD 39 ref  
VaD 
PDD/DLB 
9 
4 
-0.134 (0.139) 
0.970 (0.001) 
0.007* 
Baseline MMSE NA 52 -0.005 (0.869) 0.869 
Date Pre 2000 
2000 onwards 
17 
35 
ref 
-0.141 (0.456) 
 
0.456 
 
 Figure 1: Flow diagram of trials identified for inclusion in this review through two-tier search strategy. 
 Figure 2: Forest plot showing treatment effects from individual trials and meta-analysis results for 
AChEIs at 3 months after treatment initiation 
 Figure 3: Funnel plot of treatment effects at 3 months after treatment initiation. 
 Figure 4: Forest plot showing treatment effects from individual trials and meta-analysis results for 
AChEIs at 6 months after treatment initiation  
 Figure 5: Forest plot showing treatment effects from individual trials and meta-analysis results for 
AChEIs at 12 months after treatment initiation 
 
Figure 6: Forest plots showing treatment effects from individual trials and meta-analysis results for 
memantine at 3, 6 and 12 months after treatment initiation. 
Supplementary Material: Search terms 
1. “acetylcholinesterase inhibitor*” OR “cholinesterase inhibitor*” 
2. donepezil OR arciept* OR E2020 
3. galantamine OR galanthamine OR reminyl* OR nivalin* OR razadyne* OR lycoremine 
4. rivastigmine OR exelon* OR “SDZ ENA 713” 
5. memantine OR namenda* OR ebixa* OR axura*  OR memox OR akatinol OR abixa OR “D-145” 
OR DMAA OR “DRG-0267” 
6. Alzheimer* OR AD 
7. “vascular dement*” OR VaD 
8. DLB OR LBD OR “lewy* bod*” 
9. PDD OR “Parkinson* disease dement*” 
10. Dementia 
11. randomi?ed OR trial 
12. "meta-analysis” OR “systematic review” 
These search terms were adapted to the syntax of the databases used and combined in order to carry 
out the searches as follows 
 Reviews: (1 OR 2 OR 3 OR 4 OR 5) AND (6 OR 7 OR 8 OR 9 OR 10) AND 11 AND 12 
 Additional AD searches: (1 OR 2 OR 3 OR 4 OR 5) AND 6 AND 11 AND 12, limit 2013-current 
 Additional VaD searches: 
o (1 OR 3 OR 4) AND 7 AND 11 AND 12, limit 2013-current 
o (2 OR 5) AND 7 AND 11 AND 12, limit 2007-current 
 Additional PDD/DLB searches: 
o (1 OR 2 OR 3 OR 4) AND (8 OR 9) AND 11 AND 12, limit 2011-current 
o 5 AND (8 OR 9) AND 11 AND 12 
 
